SGR-3515

SGR-3515 is a first-in-class, orally administered small molecule dual inhibitor of the kinases Wee1 and Myt1. These kinases are critical regulators of the cell cycle and DNA damage response; they phosphorylate and inactivate cyclin-dependent kinase 1 (CDK1), allowing cells to repair DNA before mitosis. Inhibition of both Wee1 and Myt1 induces synthetic lethality in cancer cells with certain molecular vulnerabilities—particularly those with defects in DNA damage repair pathways—leading to selective anti-tumor activity. Preclinical studies have shown that SGR-3515 has superior selectivity, pharmacodynamic responses, and anti-tumor efficacy compared to single-target Wee1 or Myt1 inhibitors. The drug is being developed by Schrödinger for use as monotherapy or in combination with other agents for advanced solid tumors; it is currently undergoing Phase 1 clinical trials to assess safety, tolerability, pharmacokinetics/dynamics, and preliminary efficacy[1][4][6][7][8].